RaDaR® ST
Minimal Residual Disease (MRD) detection and recurrence monitoring across solid tumors
CommercialLaunched
Key Facts
Indication
Minimal Residual Disease (MRD) detection and recurrence monitoring across solid tumors
Phase
Commercial
Status
Launched
Company
About NeoGenomics
NeoGenomics is a publicly-traded leader in cancer diagnostics, founded in 1999, with a mission to save lives by improving patient care through precision oncology testing. The company leverages one of the largest oncology databases, with over 2 million unique patient profiles, to deliver more than 1.7 million tests annually to over 4,400 medical sites. Its strategic focus encompasses three core pillars: providing advanced testing solutions to healthcare providers, accelerating drug development for biopharma partners, and harnessing real-world data to advance personalized medicine.
View full company profile